Business Context and Reporting Period
This Form 8-K filing by Capricor Therapeutics, Inc. (CAPR) reports on events occurring at the Company's 2025 Annual Meeting of Stockholders held on May 22, 2025. The filing details the election of directors, ratification of the independent auditor, approval of a new equity incentive plan, and the advisory vote on executive compensation.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Corporate Actions
- Equity Incentive Plan Approval: Stockholders approved the Capricor Therapeutics 2025 Equity Incentive Plan. The plan reserves 3,500,000 shares of common stock for issuance to employees, directors, and consultants. The share count will automatically increase annually by 5% of outstanding shares from 2026 through 2035.
- Board of Directors Election: Eight nominees were elected to serve until the 2026 annual meeting: Frank Litvack, M.D., Linda Marbán, Ph.D., David B. Musket, George W. Dunbar, Jr., Karimah Es Sabar, Paul Auwaerter, M.D., Philip Gotwals, Ph.D., and Michael Kelliher.
- Auditor Ratification: Stockholders ratified the appointment of Rose, Snyder & Jacobs LLP as the independent registered accounting firm for the fiscal year ending December 31, 2025.
- Executive Compensation: The advisory vote on named executive officer compensation was approved.
Voting Results and Shareholder Participation
Of the 45,676,887 shares entitled to vote, holders of 30,550,197 shares were present in person or by proxy. The voting results were as follows:
| Proposal | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Election of Directors (All 8) | Varied (e.g., 17.5M for Gotwals) | Varied (e.g., 7.3M against Es Sabar) | N/A | 12,481,913 |
| Ratification of Auditor | 29,548,484 | 563,052 | 438,661 | N/A |
| 2025 Equity Incentive Plan | 9,673,779 | 8,210,461 | 184,044 | 12,481,913 |
| Executive Compensation (Say-on-Pay) | 16,442,845 | 1,467,438 | 158,001 | 12,481,913 |
Note: The Equity Incentive Plan passed despite a significant number of "Against" votes relative to "For" votes, as the "For" votes exceeded the "Against" votes.
Investor Verification Checklist
- Verify the specific terms of the 2025 Equity Incentive Plan in the definitive proxy statement (Schedule 14A) filed on April 8, 2025, as the 8-K only provides a summary.
- Review the voting results for director Karimah Es Sabar, who received the highest number of "Against" votes (7,287,853) among the nominees.
- Confirm the impact of the 3,500,000 share reserve and the 5% annual increase mechanism on future dilution.
- Check subsequent filings for the Company's financial status, as this 8-K contains no financial metrics.